Kyverna Therapeutics Inc. (KYTX)
NASDAQ: KYTX
· Real-Time Price · USD
3.53
-0.01 (-0.28%)
At close: Aug 15, 2025, 3:59 PM
3.58
1.42%
After-hours: Aug 15, 2025, 06:09 PM EDT
Kyverna Therapeutics Income Statement
Financials in USD. Fiscal
year is
undefined.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 |
Revenue | 2.02M | 2.02M | 2.02M | n/a | n/a | n/a | n/a | 282K | 282K | 282K | 282K |
Cost of Revenue | 2.14M | 2.15M | 2.13M | 2.03M | 1.91M | 1.79M | 10.02M | 9.94M | 9.5M | 9.09M | 374K |
Gross Profit | -2.14M | -2.15M | -2.13M | -2.03M | -1.91M | -1.79M | -10.02M | -9.65M | -9.22M | -8.8M | -92K |
Operating Income | -171.63M | -160.65M | -142.6M | -122.94M | -100.45M | -80.32M | -62.41M | -49.8M | -33.52M | -20.22M | -8.78M |
Interest Income | 13.12M | 15.45M | 15.36M | 12.57M | 9.1M | 4.67M | 2.28M | 1.79M | 910K | 646K | 297K |
Pretax Income | -158.7M | -145.42M | -127.48M | -110.66M | -91.63M | -75.92M | -60.37M | -48.2M | -32.73M | -19.64M | -8.5M |
Net Income | -158.7M | -145.42M | -127.48M | -110.66M | -91.63M | -75.92M | -60.37M | -48.2M | -32.73M | -19.64M | -8.5M |
Selling & General & Admin | 35.7M | 33.22M | 30.13M | 26.79M | 19.85M | 16.63M | 12.48M | 10.26M | 7.62M | 4.72M | 1.99M |
Research & Development | 135.93M | 127.43M | 112.47M | 96.15M | 80.17M | 62.84M | 49.07M | 38.98M | 25.77M | 15.78M | 7.07M |
Other Expenses | -1.06M | -1.06M | -589K | -58K | -71K | -78K | -55K | n/a | 13K | 20K | 23K |
Operating Expenses | 170.56M | 159.59M | 142.04M | 122.94M | 100.01M | 79.47M | 61.55M | 49.23M | 33.39M | 20.5M | 9.06M |
Interest Expense | 98K | 123K | 142K | 162K | 180K | 187K | 187K | 181K | 131K | 85K | 41K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 171.63M | 160.65M | 142.6M | 122.94M | 100.45M | 80.32M | 62.41M | 50.09M | 33.8M | 20.5M | 9.06M |
Income Tax Expense | n/a | n/a | 18K | 33K | 33K | 33K | 56K | 105K | 105K | 105K | 64K |
Shares Outstanding (Basic) | 43.23M | 43.22M | 43.21M | 43.16M | 43.13M | 23.75M | 43.12M | 43.12M | 43.12M | 25.8M | 43.12M |
Shares Outstanding (Diluted) | 43.23M | 43.22M | 43.21M | 43.16M | 43.13M | 23.75M | 43.12M | 43.12M | 43.12M | 25.8M | 43.12M |
EPS (Basic) | -3.67 | -3.37 | -3.46 | -3.07 | -2.63 | -2.26 | -1.57 | -1.29 | -0.93 | -0.63 | -0.2 |
EPS (Diluted) | -3.67 | -3.37 | -3.46 | -3.07 | -2.63 | -2.26 | -1.57 | -1.29 | -0.93 | -0.63 | -0.2 |
EBITDA | -162.62M | -146.44M | -125.2M | -108.46M | -89.54M | -73.93M | -58.47M | -46.4M | -31.42M | -18.79M | -8.08M |
EBIT | -158.6M | -145.3M | -127.33M | -110.49M | -91.45M | -75.73M | -60.18M | -48.01M | -32.6M | -19.55M | -8.46M |
Depreciation & Amortization | 1.62M | 2.15M | 2.13M | 2.03M | 1.91M | 1.79M | 1.71M | 1.62M | 1.18M | 768K | 374K |